Compare ATLC & SLBT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
| Metric | ATLC | SLBT |
|---|---|---|
| Founded | 1996 | N/A |
| Country | United States | Taiwan |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | |
| Sector | Finance | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 1.5B |
| IPO Year | 2009 | 2025 |
| Metric | ATLC | SLBT |
|---|---|---|
| Price | $94.22 | $2.10 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 7 | 0 |
| Target Price | ★ $90.00 | N/A |
| AVG Volume (30 Days) | ★ 111.5K | 46.5K |
| Earning Date | 05-11-2026 | N/A |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 24.95 | N/A |
| EPS | ★ 4.74 | N/A |
| Revenue | ★ $1,968,399,000.00 | N/A |
| Revenue This Year | $477.21 | N/A |
| Revenue Next Year | $10.42 | N/A |
| P/E Ratio | $19.54 | ★ N/A |
| Revenue Growth | ★ 50.09 | N/A |
| 52 Week Low | $47.50 | $2.51 |
| 52 Week High | $114.34 | $6.25 |
| Indicator | ATLC | SLBT |
|---|---|---|
| Relative Strength Index (RSI) | 44.18 | 33.37 |
| Support Level | $90.43 | N/A |
| Resistance Level | $93.21 | $3.36 |
| Average True Range (ATR) | 3.45 | 0.25 |
| MACD | 0.01 | -0.01 |
| Stochastic Oscillator | 46.26 | 2.67 |
Atlanticus Holdings Corp is a financial technology company powering more inclusive financial solutions for Everyday Americans. It provides technology and other support services to lenders who offer an array of financial products and services to consumers. The company's products and services are reported through two reportable segments. Credit as a Service (CaaS) offers products including private label credit cards using the Fortiva and Curae brand names as well as merchant-associated brands and Auto Finance provides purchase and/or service loans secured by automobiles from or for, and also provides floor-plan financing for, a pre-qualified network of independent automotive dealers and automotive finance companies in the buy-here, pay-here used car business.
SL Science Holding Ltd is a biomedical company specialized in developing cellular and gene therapies advancing regenerative medicine and cancer treatment. It utilizes immune stem cells to target cancer and bovine-derived milk exosomes to regenerate damaged tissues, thus potentially offering expansive medical applications for its products. With proprietary technologies such as Armed-T and Gamma Delta T cells, as well as exosome applications in skincare and cancer recovery. It operates in three segments namely Exosome products, CD-19 Armed-T products, and GDT cell therapy products. It derives revenue from Exosome products segment.